| Name | Title | Contact Details |
|---|
Scale your team with high-quality, vetted professionals. 🚀 MSH is a global technology and talent solutions provider that empowers people and the places they work to thrive. The companys leading-edge services and support provide organizations with the business intelligence and high-quality, vetted candidates they need to succeed at a speed and scale others cannot in 35+ markets across three continents. By engaging MSHs human-centered and collaborative platform, hiring leaders and talent professionals are empowered to find the highest quality candidates, while putting the candidate experience front and center. Founded in 2011 and headquartered in Fort Lauderdale, Fla., MSH is certified as a Minority Business Enterprise by the National Minority Supplier Development Council.
Valent Partners are an integrated team of strategists, business leaders and technologists obsessed with helping our clients reach new heights. We approach each situation through a holistic business and technology lens, advising on and delivering solutions that help your organization adapt ahead of your competition. You have a goal. Well get you there. If your organization is interested in finding ways that technology can improve your performance, profitability, and growth, we can help. Contact Valent Partners today to arrange a consultation on the challenges you face. Your Digital Journey begins here.
With over 180 franchises awarded and a total of over 2,700 courts, Pickleball Kingdom is the largest indoor pickleball entity in the world. Its high revenue and labor-light model make it the best in class for Americas fastest growing sport.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.